Catheter Precision, Inc. filings document material events, operating results, shareholder votes, capital-structure matters, and governance disclosures for a NYSE American-listed company. The records include 8-K reports on financial results and business updates tied to the company’s electrophysiology products, including VIVO and LockeT, as well as strategic expansion activity.
VTAK’s proxy and current-report filings also cover stockholder approval matters, common-stock issuance proposals, convertible preferred stock series, promissory note amendments, royalty-right exchanges, related-party transaction disclosures, and other material agreements. These filings frame the company’s public reporting around medical device commercialization, financing arrangements, and corporate governance.
Catheter Precision, Inc. implemented a 1-for-19 reverse stock split of its common stock after stockholder authorization, effective at 12:01 a.m. ET on August 15, 2025. The company combined every 19 issued shares into one share and reduced issued and outstanding common shares from approximately 23,327,516 to approximately 1,227,764. The common stock continues to trade under the symbol VTAK on the NYSE American on a split-adjusted basis and received a new CUSIP number.
Authorized capital remains unchanged at 10 million preferred and 60 million common shares. Proportionate adjustments were made to outstanding stock options, warrants, conversion prices and shares available under incentive plans. Fractional shares will not be issued; holders entitled to fractions will receive cash pro rata from aggregated fractional-share sales, net of customary fees.
Armistice Capital, LLC and Steven Boyd report collective beneficial ownership of 1,120,635 shares of Catheter Precision, Inc. common stock, representing 4.99% of the class. The filing states the Reporting Persons hold shared voting and dispositive power over these shares and have no sole voting or dispositive power. Armistice is the investment manager of the Master Fund, which directly holds the shares, and the Master Fund disclaims beneficial ownership by virtue of the investment management agreement. The Reporting Persons certify the holdings are in the ordinary course of business and not for the purpose of changing or influencing control.
James Joseph Caruso, a director of Catheter Precision, Inc. (VTAK), reported an option award on 08/12/2025. The filing shows an acquisition of 50,000 stock options with an exercise price of $0.18. The options are exercisable beginning 08/12/2025 and reference an 08/12/2035 date in the derivative table, with the filing stating the options vest one-third per year beginning on the first anniversary of the grant. After this transaction Caruso beneficially owns the 50,000 underlying shares directly. The form is signed 08/14/2025.
Catheter Precision, Inc. (VTAK) reported an insider transaction in which a company director was granted 50,000 stock options with an exercise price of $0.18. The options were granted on the reported transaction date and vest one-third each year beginning on the first anniversary of the grant. The options are exercisable through the expiration date in 2035, and the reporting person holds 50,000 underlying shares post-transaction.
This disclosure is a routine director equity award that creates long-term option-based compensation and the right to acquire 50,000 shares at the stated strike price subject to the vesting schedule.
David A. Jenkins, Executive Chairman of the Board of Catheter Precision, Inc. (VTAK), was granted 500,000 stock option awards on 08/12/2025. The options have an exercise price of $0.18 per share, an exercisable date listed as 08/12/2025 and an expiration date of 08/12/2035. The filing shows 500,000 underlying shares of common stock beneficially owned following the transaction, held directly. The options vest at 20% per year beginning on the first anniversary of the grant date, according to the explanation in the filing.
Catheter Precision, Inc. (VTAK) reported accelerating product sales and continued investment in new technologies while also recording material operating losses and liquidity strain. Product revenue totaled $355 thousand for the six months ended June 30, 2025, up from $175 thousand a year earlier, with U.S. sales of $308 thousand in the period. The company incurred a six-month net loss of $9.5 million and used $4.6 million of cash in operating activities.
Balance sheet items highlight short-term pressure: cash and cash equivalents were $0.8 million, working capital showed a $2.6 million deficit, and accumulated deficit reached $301.5 million. Material financing and corporate actions in 2025 included a May PIPE that generated $1.5 million in cash (and two convertible notes received as consideration), an ATM program that produced $1.7 million gross through June 30, 2025, formation of subsidiaries Cardionomix and KardioNav, acquisition of CPNS System assets, and an April 2025 U.S. patent for LockeT. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional financing.
Catheter Precision, Inc. furnished a Current Report on Form 8-K to announce that it issued a press release on August 11, 2025 reporting its financial results for the three and six months ended June 30, 2025. The company states the full press release is attached as Exhibit 99.1 and is incorporated by reference into the report. The company also clarifies that the information furnished under Item 2.02, including Exhibit 99.1, is being furnished and not filed for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into future SEC filings unless expressly stated.
Catheter Precision, Inc. (NYSE American: VTAK) is updating its at-the-market (ATM) program. The new prospectus supplement limits additional issuances to $1.53 million of common stock that may be sold through Ladenburg Thalmann.
Key figures:
- Shares already sold: 8,649,526 for gross proceeds of $2.73 million during the last 12 months.
- Current public float: 21,336,987 shares worth $12.8 million (calculated at $0.60, the highest close in the past 60 days).
- Form S-3 Rule I.B.6 cap: While float remains below $75 million, VTAK may sell only one-third of its float every 12 months; $1.53 million capacity remains after prior sales.
- Recent market price: $0.17 per share on 4 Aug 2025, far below the float-calculation price.
Should the float rise—or exceed $75 million—the company may expand the program and will file another supplement. Prospective investors are urged to review the incorporated “Risk Factors,” particularly potential dilution and price pressure from continued share sales.
Catheter Precision, Inc. (VTAK) filed an 8-K detailing annual-meeting results and a forthcoming reverse stock split.
Only 5.81 M of 12.59 M eligible shares (46.1%) were voted. Six proposals passed: (1) re-election of director Martin Colombatto (2.57 M for); (2) issuance of up to 4.29 M shares on Series L warrant exercise; (3) issuance of up to 8.57 M shares on Series B preferred conversion; (4) issuance of 0.26 M shares for placement-agent warrants; (5) authorization of a reverse split between 1-for-5 and 1-for-19; (6) ratification of WithumSmith+Brown as auditor (4.96 M for).
The board has chosen the maximum ratio, implementing a 1-for-19 reverse split effective 15 Aug 2025. Shares outstanding will be reduced from ~23.3 M to ~1.2 M; fractional shares will be paid in cash. Authorized capital (60 M common, 10 M preferred) is unchanged, and ownership percentages are unaffected apart from cash-settled fractions. The action seeks to restore compliance with the NYSE American’s minimum bid requirement. VTAK will continue trading under its ticker, adopting new CUSIP 74933X 708.
Catheter Precision, Inc. (VTAK) filed a Form S-8 on 26 June 2025 to register shares issuable under two employee equity programs: (1) the Catheter Precision 2023 Equity Incentive Plan and (2) a stand-alone stock-option grant dated 6 Jan 2025 to CFO Philip Anderson. The filing allows the Company to issue these shares to employees without additional SEC registration, thereby facilitating equity-based compensation.
Registrant profile: Delaware corporation, non-accelerated filer, smaller reporting company, principal offices in Fort Mill, SC. The registration statement incorporates by reference the Company’s 2024 Form 10-K (filed 31 Mar 2025, amended 30 Apr 2025), Q1-2025 Form 10-Q (filed 14 May 2025) and thirteen Form 8-Ks filed between 7 Jan and 13 Jun 2025. These filings collectively provide investors the requisite financial and operational background.
Legal & governance highlights: The document reiterates broad indemnification protections for directors and officers under Delaware law and the Company’s bylaws, including advancement of expenses. The SEC’s longstanding position that indemnification for Securities Act liabilities is unenforceable is also acknowledged.
Exhibits of note: (i) legal opinion on share legality (Ex. 5.1), (ii) auditor consent (Ex. 23.2), (iii) full 2023 Incentive Plan (Ex. 99.1) and the individual non-plan option award (Ex. 99.2). Exhibit 107 contains the fee table; specific share counts and aggregate offering value are not provided in the excerpt.
Investor impact: Because S-8 registrations are routine administrative matters with no immediate cash proceeds, the filing is operationally neutral. Over time, however, issuances under the plan will increase the fully diluted share count and may introduce incremental dilution.